Updated on 7 April 2015
uniQure will undertake manufacturing of all gene therapy products under the collaboration
Singapore: The companies anticipate the collaboration to be effective during the second quarter of 2015.
The collaboration includes uniQure's proprietary gene therapy program for congestive heart failure that is intended to restore the heart's ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction.
Beyond cardiovascular diseases, the agreement also includes the potential for target-exclusive collaboration in other disease areas.
In total, the companies may collaborate on ten targets, including S100A1.
uniQure will lead discovery efforts and be responsible for manufacturing of clinical and commercial supplies using its vector technologies and its industrial, proprietary insect-cell based manufacturing platform.
BMS will be solely responsible for commercialization of all products from the collaboration.